Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents

Medical Oncology

Volumn 34, Issue 9, 2017, Pages

  Bando, Yukari ^a   Hinata, Nobuyuki ^a   Terakawa, Tomoaki ^a   Furukawa, Junya ^a   Harada, Ken ichi ^a   Nakano, Yuzo ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cabazitaxel; Chemotherapy; Metastatic castration resistant prostate cancer; Sequential therapy

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR TARGETING AGENT; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

AGED; ALOPECIA; ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG ACTIVITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TAXOIDS; TREATMENT OUTCOME;

EID: 85027858564     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-017-1024-0     Document Type: Article

References (13)

1. Cornford P, Bellmunt J, Bolla M, Briers E, Santis MD, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.
2. Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2015;68:228–35.
3. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376:1147–54.
4. Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13:309–18.
5. Wissing MD, Coenen JL, Van Den Berg P, Westgeest HM, van den Eerwegh AJ, van Oort IM, et al. CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer. 2015;136:E760–72.
6. Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96:498–506.
7. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St. Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604.
8. Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015;26:2044–56.
9. Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate Cancer, Version 1.2016. J Natl Compr Cancer Netw. 2016;14:19–30.
10. Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;66:459–65.
11. Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016;56:93–100.
12. Halabi S, Lin CY, Small EJ, Armtrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729–37.
13. Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, et al. Enzalutamide as a fourth-or fifth-line treatment option for metastatic castration-resistant prostate cancer. Oncology. 2016;91:267–73.